Geneva, Switzerland, February 3, 2026-Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results